PMID- 34584206 OWN - NLM STAT- MEDLINE DCOM- 20211221 LR - 20211221 IS - 2399-3642 (Electronic) IS - 2399-3642 (Linking) VI - 4 IP - 1 DP - 2021 Sep 28 TI - Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity. PG - 1137 LID - 10.1038/s42003-021-02657-2 [doi] LID - 1137 AB - Idiosyncratic drug toxicity (IDT) associated with specific human leukocyte antigen (HLA) allotype is a rare and unpredictable life-threatening adverse drug reaction for which prospective mechanistic studies in humans are difficult. Here, we show the importance of immune tolerance for IDT onset and determine whether it is susceptible to a common IDT, HLA-B*57:01-mediated abacavir (ABC)-induced hypersensitivity (AHS), using CD4(+) T cell-depleted programmed death-1 receptor (PD-1)-deficient HLA-B*57:01 transgenic mice (B*57:01-Tg/PD-1(-/-)). Although AHS is not observed in B*57:01-Tg mice, ABC treatment increases the proportion of cytokine- and cytolytic granule-secreting effector memory CD8(+) T cells in CD4(+) T cell-depleted B*57:01-Tg/PD-1(-/-) mice, thereby inducing skin toxicity with CD8(+) T cell infiltration, mimicking AHS. Our results demonstrate that individual differences in the immune tolerance system, including PD-1(high)CD8(+) T cells and regulatory CD4(+) T cells, may affect the susceptibility of humans to HLA-mediated IDT in humans. CI - (c) 2021. The Author(s). FAU - Susukida, Takeshi AU - Susukida T AUID- ORCID: 0000-0003-1512-0753 AD - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan. AD - Laboratory of Cancer Biology and Immunology, Section of Host Defences, Institute of Natural Medicine, University of Toyama, Toyama, Japan. FAU - Kuwahara, Saki AU - Kuwahara S AD - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan. FAU - Song, Binbin AU - Song B AD - Key Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, School of Pharmacy, Minzu University of China, 100081, Beijing, China. FAU - Kazaoka, Akira AU - Kazaoka A AD - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan. FAU - Aoki, Shigeki AU - Aoki S AUID- ORCID: 0000-0003-2821-0651 AD - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan. aokishigeki@chiba-u.jp. FAU - Ito, Kousei AU - Ito K AD - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210928 PL - England TA - Commun Biol JT - Communications biology JID - 101719179 RN - 0 (Dideoxynucleosides) RN - 0 (Histocompatibility Antigens Class I) RN - WR2TIP26VS (abacavir) SB - IM MH - Animals MH - Dideoxynucleosides/*administration & dosage MH - Histocompatibility Antigens Class I/*metabolism MH - Immune Tolerance/*genetics MH - Mice MH - Mice, Transgenic PMC - PMC8479119 COIS- The authors declare no competing interests. EDAT- 2021/09/30 06:00 MHDA- 2021/12/22 06:00 PMCR- 2021/09/28 CRDT- 2021/09/29 06:45 PHST- 2020/11/19 00:00 [received] PHST- 2021/09/10 00:00 [accepted] PHST- 2021/09/29 06:45 [entrez] PHST- 2021/09/30 06:00 [pubmed] PHST- 2021/12/22 06:00 [medline] PHST- 2021/09/28 00:00 [pmc-release] AID - 10.1038/s42003-021-02657-2 [pii] AID - 2657 [pii] AID - 10.1038/s42003-021-02657-2 [doi] PST - epublish SO - Commun Biol. 2021 Sep 28;4(1):1137. doi: 10.1038/s42003-021-02657-2.